#FORMAT=WebAnno TSV 3.2
#T_SP=webanno.custom.Referent|entity|infstat
#T_RL=webanno.custom.Coref|type|BT_webanno.custom.Referent


#Text=4 .
1-1	0-1	4	time	new	coref	16-22[108_0]
1-2	2-3	.	_	_	_	_

#Text=Discussion
2-1	4-14	Discussion	abstract	new	_	_

#Text=Diet interventions are well-established strategies to reduce body weight and improve glucose metabolism , however no evidence exists about the effects of periodic fasting on NAFLD .
3-1	15-19	Diet	organization|event[4]	new|new[4]	coref|coref	11-8[75_4]|11-8[75_4]
3-2	20-33	interventions	event[4]	new[4]	_	_
3-3	34-37	are	_	_	_	_
3-4	38-54	well-established	_	_	_	_
3-5	55-65	strategies	abstract	new	_	_
3-6	66-68	to	_	_	_	_
3-7	69-75	reduce	_	_	_	_
3-8	76-80	body	object|abstract[7]	new|new[7]	coref|coref|coref|coref	12-16[0_7]|19-3[130_0]|12-16[0_7]|19-3[130_0]
3-9	81-87	weight	abstract[7]	new[7]	_	_
3-10	88-91	and	_	_	_	_
3-11	92-99	improve	abstract|abstract	new|new	coref|none|none|none|coref|none|none|none	23-19[162_0]|3-11|3-11[0_279]|34-18|23-19[162_0]|3-11|3-11[0_279]|34-18
3-12	100-107	glucose	substance|abstract[9]	new|new[9]	_	_
3-13	108-118	metabolism	abstract[9]	new[9]	_	_
3-14	119-120	,	_	_	_	_
3-15	121-128	however	_	_	_	_
3-16	129-131	no	abstract[10]	new[10]	coref	19-7[131_10]
3-17	132-140	evidence	abstract[10]	new[10]	_	_
3-18	141-147	exists	_	_	_	_
3-19	148-153	about	_	_	_	_
3-20	154-157	the	abstract[11]	new[11]	_	_
3-21	158-165	effects	abstract[11]	new[11]	_	_
3-22	166-168	of	abstract[11]	new[11]	_	_
3-23	169-177	periodic	abstract[11]|abstract[12]	new[11]|new[12]	coref	4-12[16_12]
3-24	178-185	fasting	abstract[11]|abstract[12]	new[11]|new[12]	_	_
3-25	186-188	on	abstract[11]|abstract[12]	new[11]|new[12]	_	_
3-26	189-194	NAFLD	abstract[11]|abstract[12]|substance	new[11]|new[12]|new	coref	10-5
3-27	195-196	.	_	_	_	_

#Text=This study is the first to show the beneficial effects of periodic fasting on fatty liver .
4-1	197-201	This	abstract[14]	new[14]	coref	5-4[20_14]
4-2	202-207	study	abstract[14]	new[14]	_	_
4-3	208-210	is	_	_	_	_
4-4	211-214	the	_	_	_	_
4-5	215-220	first	_	_	_	_
4-6	221-223	to	_	_	_	_
4-7	224-228	show	_	_	_	_
4-8	229-232	the	abstract[15]	new[15]	_	_
4-9	233-243	beneficial	abstract[15]	new[15]	_	_
4-10	244-251	effects	abstract[15]	new[15]	_	_
4-11	252-254	of	abstract[15]	new[15]	_	_
4-12	255-263	periodic	abstract[15]|abstract[16]	new[15]|giv[16]	coref	5-29[0_16]
4-13	264-271	fasting	abstract[15]|abstract[16]	new[15]|giv[16]	_	_
4-14	272-274	on	abstract[15]|abstract[16]	new[15]|giv[16]	_	_
4-15	275-280	fatty	abstract[15]|abstract[16]|object[17]	new[15]|giv[16]|new[17]	coref	5-16[24_17]
4-16	281-286	liver	abstract[15]|abstract[16]|object[17]	new[15]|giv[16]|new[17]	_	_
4-17	287-288	.	_	_	_	_

#Text=The results of our study supported the hypothesis that FLI , a surrogate parameter of fatty liver , significantly decreases in individuals with and without T2DM after a fasting intervention of at least 6 days .
5-1	289-292	The	abstract[18]	new[18]	coref	8-1[44_18]
5-2	293-300	results	abstract[18]	new[18]	_	_
5-3	301-303	of	abstract[18]	new[18]	_	_
5-4	304-307	our	abstract[18]|person|abstract[20]	new[18]|acc|giv[20]	coref|ana|coref|ana	6-3[0_20]|8-1|6-3[0_20]|8-1
5-5	308-313	study	abstract[18]|abstract[20]	new[18]|giv[20]	_	_
5-6	314-323	supported	_	_	_	_
5-7	324-327	the	abstract[21]	new[21]	coref	18-4[126_21]
5-8	328-338	hypothesis	abstract[21]	new[21]	_	_
5-9	339-343	that	_	_	_	_
5-10	344-347	FLI	abstract	new	appos	5-12[23_0]
5-11	348-349	,	_	_	_	_
5-12	350-351	a	abstract[23]	giv[23]	coref	9-15[0_23]
5-13	352-361	surrogate	abstract[23]	giv[23]	_	_
5-14	362-371	parameter	abstract[23]	giv[23]	_	_
5-15	372-374	of	abstract[23]	giv[23]	_	_
5-16	375-380	fatty	abstract[23]|object[24]	giv[23]|giv[24]	coref	7-7[0_24]
5-17	381-386	liver	abstract[23]|object[24]	giv[23]|giv[24]	_	_
5-18	387-388	,	_	_	_	_
5-19	389-402	significantly	_	_	_	_
5-20	403-412	decreases	_	_	_	_
5-21	413-415	in	_	_	_	_
5-22	416-427	individuals	person	new	_	_
5-23	428-432	with	_	_	_	_
5-24	433-436	and	_	_	_	_
5-25	437-444	without	_	_	_	_
5-26	445-449	T2DM	event	new	coref	27-20
5-27	450-455	after	_	_	_	_
5-28	456-457	a	event[28]	new[28]	coref	12-25[0_28]
5-29	458-465	fasting	abstract|event[28]	giv|new[28]	coref	6-13
5-30	466-478	intervention	event[28]	new[28]	_	_
5-31	479-481	of	event[28]	new[28]	_	_
5-32	482-484	at	event[28]|time[29]	new[28]|new[29]	_	_
5-33	485-490	least	event[28]|time[29]	new[28]|new[29]	_	_
5-34	491-492	6	event[28]|time[29]	new[28]|new[29]	_	_
5-35	493-497	days	event[28]|time[29]	new[28]|new[29]	_	_
5-36	498-499	.	_	_	_	_

#Text=The prospective study design according to a standardized protocol with a well-established fasting technique and a close clinical monitoring was a strength of this study .
6-1	500-503	The	abstract[31]	new[31]	coref	6-21[36_31]
6-2	504-515	prospective	abstract[31]	new[31]	_	_
6-3	516-521	study	abstract|abstract[31]	giv|new[31]	coref	6-24[37_0]
6-4	522-528	design	abstract[31]	new[31]	_	_
6-5	529-538	according	abstract[31]	new[31]	_	_
6-6	539-541	to	abstract[31]	new[31]	_	_
6-7	542-543	a	abstract[31]|abstract[32]	new[31]|new[32]	_	_
6-8	544-556	standardized	abstract[31]|abstract[32]	new[31]|new[32]	_	_
6-9	557-565	protocol	abstract[31]|abstract[32]	new[31]|new[32]	_	_
6-10	566-570	with	abstract[31]|abstract[32]	new[31]|new[32]	_	_
6-11	571-572	a	abstract[31]|abstract[32]|abstract[34]	new[31]|new[32]|new[34]	_	_
6-12	573-589	well-established	abstract[31]|abstract[32]|abstract[34]	new[31]|new[32]|new[34]	_	_
6-13	590-597	fasting	abstract[31]|abstract[32]|abstract|abstract[34]	new[31]|new[32]|giv|new[34]	coref	13-3[89_0]
6-14	598-607	technique	abstract[31]|abstract[32]|abstract[34]	new[31]|new[32]|new[34]	_	_
6-15	608-611	and	abstract[31]|abstract[32]	new[31]|new[32]	_	_
6-16	612-613	a	abstract[31]|abstract[32]|abstract[35]	new[31]|new[32]|new[35]	_	_
6-17	614-619	close	abstract[31]|abstract[32]|abstract[35]	new[31]|new[32]|new[35]	_	_
6-18	620-628	clinical	abstract[31]|abstract[32]|abstract[35]	new[31]|new[32]|new[35]	_	_
6-19	629-639	monitoring	abstract[31]|abstract[32]|abstract[35]	new[31]|new[32]|new[35]	_	_
6-20	640-643	was	_	_	_	_
6-21	644-645	a	abstract[36]	giv[36]	_	_
6-22	646-654	strength	abstract[36]	giv[36]	_	_
6-23	655-657	of	abstract[36]	giv[36]	_	_
6-24	658-662	this	abstract[36]|abstract[37]	giv[36]|giv[37]	coref	17-8[123_37]
6-25	663-668	study	abstract[36]|abstract[37]	giv[36]|giv[37]	_	_
6-26	669-670	.	_	_	_	_

#Text=Weight reduction and improvement of fatty liver indicators are known to be interrelated .
7-1	671-677	Weight	person|abstract[39]	new|new[39]	coref|coref	8-5[45_39]|8-5[45_39]
7-2	678-687	reduction	abstract[39]	new[39]	_	_
7-3	688-691	and	_	_	_	_
7-4	692-703	improvement	abstract[40]	new[40]	_	_
7-5	704-706	of	abstract[40]	new[40]	_	_
7-6	707-712	fatty	abstract[40]|abstract[42]	new[40]|new[42]	_	_
7-7	713-718	liver	abstract[40]|object|abstract[42]	new[40]|giv|new[42]	coref	8-15[49_0]
7-8	719-729	indicators	abstract[40]|abstract[42]	new[40]|new[42]	_	_
7-9	730-733	are	_	_	_	_
7-10	734-739	known	_	_	_	_
7-11	740-742	to	_	_	_	_
7-12	743-745	be	_	_	_	_
7-13	746-758	interrelated	_	_	_	_
7-14	759-760	.	_	_	_	_

#Text=Our results indicate that even a modest reduction of BMI improved surrogate markers of fatty liver .
8-1	761-764	Our	person|abstract[44]	giv|giv[44]	ana|ana	18-1|18-1
8-2	765-772	results	abstract[44]	giv[44]	_	_
8-3	773-781	indicate	_	_	_	_
8-4	782-786	that	_	_	_	_
8-5	787-791	even	abstract[45]	giv[45]	_	_
8-6	792-793	a	abstract[45]	giv[45]	_	_
8-7	794-800	modest	abstract[45]	giv[45]	_	_
8-8	801-810	reduction	abstract[45]	giv[45]	_	_
8-9	811-813	of	abstract[45]	giv[45]	_	_
8-10	814-817	BMI	abstract[45]|abstract	giv[45]|new	coref	9-21
8-11	818-826	improved	abstract[48]	new[48]	_	_
8-12	827-836	surrogate	abstract|abstract[48]	new|new[48]	_	_
8-13	837-844	markers	abstract[48]	new[48]	_	_
8-14	845-847	of	abstract[48]	new[48]	_	_
8-15	848-853	fatty	abstract[48]|object[49]	new[48]|giv[49]	coref	28-13[0_49]
8-16	854-859	liver	abstract[48]|object[49]	new[48]|giv[49]	_	_
8-17	860-861	.	_	_	_	_

#Text=Indeed , in nearly half of the subjects in the highest risk category ( FLI > 60 ) , a BMI reduction of less than 5 % was sufficient to induce a shift to a lower risk category .
9-1	862-868	Indeed	_	_	_	_
9-2	869-870	,	_	_	_	_
9-3	871-873	in	_	_	_	_
9-4	874-880	nearly	quantity[50]	new[50]	_	_
9-5	881-885	half	quantity[50]	new[50]	_	_
9-6	886-888	of	quantity[50]	new[50]	_	_
9-7	889-892	the	quantity[50]|person[51]	new[50]|new[51]	coref	16-14[106_51]
9-8	893-901	subjects	quantity[50]|person[51]	new[50]|new[51]	_	_
9-9	902-904	in	quantity[50]|person[51]	new[50]|new[51]	_	_
9-10	905-908	the	quantity[50]|person[51]|abstract[53]	new[50]|new[51]|new[53]	_	_
9-11	909-916	highest	quantity[50]|person[51]|abstract[53]	new[50]|new[51]|new[53]	_	_
9-12	917-921	risk	quantity[50]|person[51]|abstract|abstract[53]	new[50]|new[51]|new|new[53]	coref	9-37
9-13	922-930	category	quantity[50]|person[51]|abstract[53]	new[50]|new[51]|new[53]	_	_
9-14	931-932	(	_	_	_	_
9-15	933-936	FLI	abstract	giv	coref	29-20
9-16	937-938	>	_	_	_	_
9-17	939-941	60	quantity	new	_	_
9-18	942-943	)	_	_	_	_
9-19	944-945	,	_	_	_	_
9-20	946-947	a	abstract[57]	new[57]	coref	20-16[142_57]
9-21	948-951	BMI	organization|abstract[57]	giv|new[57]	_	_
9-22	952-961	reduction	abstract[57]	new[57]	_	_
9-23	962-964	of	abstract[57]	new[57]	_	_
9-24	965-969	less	abstract[57]|quantity[58]	new[57]|new[58]	_	_
9-25	970-974	than	abstract[57]|quantity[58]	new[57]|new[58]	_	_
9-26	975-976	5	abstract[57]|quantity[58]	new[57]|new[58]	_	_
9-27	977-978	%	abstract[57]|quantity[58]	new[57]|new[58]	_	_
9-28	979-982	was	_	_	_	_
9-29	983-993	sufficient	_	_	_	_
9-30	994-996	to	_	_	_	_
9-31	997-1003	induce	_	_	_	_
9-32	1004-1005	a	event[59]	new[59]	_	_
9-33	1006-1011	shift	event[59]	new[59]	_	_
9-34	1012-1014	to	_	_	_	_
9-35	1015-1016	a	abstract[61]	new[61]	_	_
9-36	1017-1022	lower	abstract[61]	new[61]	_	_
9-37	1023-1027	risk	abstract|abstract[61]	giv|new[61]	_	_
9-38	1028-1036	category	abstract[61]	new[61]	_	_
9-39	1037-1038	.	_	_	_	_

#Text=In most patients , NAFLD is associated with features of metabolic syndrome , central obesity , elevated blood pressure , dyslipidemia , hyperglycemia , and insulin resistance .
10-1	1039-1041	In	_	_	_	_
10-2	1042-1046	most	person[62]	new[62]	coref	29-26[221_62]
10-3	1047-1055	patients	person[62]	new[62]	_	_
10-4	1056-1057	,	_	_	_	_
10-5	1058-1063	NAFLD	substance	giv	coref	19-19
10-6	1064-1066	is	_	_	_	_
10-7	1067-1077	associated	_	_	_	_
10-8	1078-1082	with	_	_	_	_
10-9	1083-1091	features	abstract[64]	new[64]	_	_
10-10	1092-1094	of	abstract[64]	new[64]	_	_
10-11	1095-1104	metabolic	abstract[64]|person|abstract[66]	new[64]|new|new[66]	coref|coref	21-2|21-2
10-12	1105-1113	syndrome	abstract[64]|abstract[66]	new[64]|new[66]	_	_
10-13	1114-1115	,	abstract[64]	new[64]	_	_
10-14	1116-1123	central	abstract[64]|abstract[67]	new[64]|new[67]	coref	27-14[0_67]
10-15	1124-1131	obesity	abstract[64]|abstract[67]	new[64]|new[67]	_	_
10-16	1132-1133	,	abstract[64]	new[64]	_	_
10-17	1134-1142	elevated	abstract[64]|abstract[68]	new[64]|new[68]	_	_
10-18	1143-1148	blood	abstract[64]|abstract[68]	new[64]|new[68]	_	_
10-19	1149-1157	pressure	abstract[64]|abstract[68]	new[64]|new[68]	_	_
10-20	1158-1159	,	abstract[64]	new[64]	_	_
10-21	1160-1172	dyslipidemia	abstract[64]|abstract	new[64]|new	_	_
10-22	1173-1174	,	abstract[64]	new[64]	_	_
10-23	1175-1188	hyperglycemia	abstract[64]|abstract	new[64]|new	_	_
10-24	1189-1190	,	abstract[64]	new[64]	_	_
10-25	1191-1194	and	abstract[64]	new[64]	_	_
10-26	1195-1202	insulin	abstract[64]|event|abstract[72]	new[64]|new|new[72]	coref|coref|coref|coref	27-16|27-16[200_72]|27-16|27-16[200_72]
10-27	1203-1213	resistance	abstract[64]|abstract[72]	new[64]|new[72]	_	_
10-28	1214-1215	.	_	_	_	_

#Text=Although these pathologies can be addressed by lifestyle interventions , in daily life the adherence to the necessary lifestyle changes is poor , resulting in suboptimal outcomes .
11-1	1216-1224	Although	_	_	_	_
11-2	1225-1230	these	abstract[73]	new[73]	_	_
11-3	1231-1242	pathologies	abstract[73]	new[73]	_	_
11-4	1243-1246	can	_	_	_	_
11-5	1247-1249	be	_	_	_	_
11-6	1250-1259	addressed	_	_	_	_
11-7	1260-1262	by	_	_	_	_
11-8	1263-1272	lifestyle	abstract|event[75]	new|giv[75]	coref|coref	11-19|11-19
11-9	1273-1286	interventions	event[75]	giv[75]	_	_
11-10	1287-1288	,	_	_	_	_
11-11	1289-1291	in	_	_	_	_
11-12	1292-1297	daily	abstract[76]	new[76]	coref	12-24[88_76]
11-13	1298-1302	life	abstract[76]	new[76]	_	_
11-14	1303-1306	the	event[77]	new[77]	coref	16-43[117_77]
11-15	1307-1316	adherence	event[77]	new[77]	_	_
11-16	1317-1319	to	event[77]	new[77]	_	_
11-17	1320-1323	the	event[77]|abstract[79]	new[77]|new[79]	_	_
11-18	1324-1333	necessary	event[77]|abstract[79]	new[77]|new[79]	_	_
11-19	1334-1343	lifestyle	event[77]|abstract|abstract[79]	new[77]|giv|new[79]	coref	16-43
11-20	1344-1351	changes	event[77]|abstract[79]	new[77]|new[79]	_	_
11-21	1352-1354	is	_	_	_	_
11-22	1355-1359	poor	_	_	_	_
11-23	1360-1361	,	_	_	_	_
11-24	1362-1371	resulting	_	_	_	_
11-25	1372-1374	in	_	_	_	_
11-26	1375-1385	suboptimal	abstract[80]	new[80]	coref	16-39[115_80]
11-27	1386-1394	outcomes	abstract[80]	new[80]	_	_
11-28	1395-1396	.	_	_	_	_

#Text=In contrast , in pragmatic programs there is a greater benefit in a more substantial weight loss , particularly at early stages of the intervention period .
12-1	1397-1399	In	_	_	_	_
12-2	1400-1408	contrast	abstract	new	coref	16-2
12-3	1409-1410	,	_	_	_	_
12-4	1411-1413	in	_	_	_	_
12-5	1414-1423	pragmatic	abstract[82]	new[82]	_	_
12-6	1424-1432	programs	abstract[82]	new[82]	_	_
12-7	1433-1438	there	_	_	_	_
12-8	1439-1441	is	_	_	_	_
12-9	1442-1443	a	abstract[83]	new[83]	_	_
12-10	1444-1451	greater	abstract[83]	new[83]	_	_
12-11	1452-1459	benefit	abstract[83]	new[83]	_	_
12-12	1460-1462	in	abstract[83]	new[83]	_	_
12-13	1463-1464	a	abstract[83]|abstract[85]	new[83]|new[85]	coref	23-6[0_85]
12-14	1465-1469	more	abstract[83]|abstract[85]	new[83]|new[85]	_	_
12-15	1470-1481	substantial	abstract[83]|abstract[85]	new[83]|new[85]	_	_
12-16	1482-1488	weight	abstract[83]|abstract|abstract[85]	new[83]|giv|new[85]	coref	13-8
12-17	1489-1493	loss	abstract[83]|abstract[85]	new[83]|new[85]	_	_
12-18	1494-1495	,	_	_	_	_
12-19	1496-1508	particularly	abstract[86]	new[86]	_	_
12-20	1509-1511	at	abstract[86]	new[86]	_	_
12-21	1512-1517	early	abstract[86]	new[86]	_	_
12-22	1518-1524	stages	abstract[86]	new[86]	_	_
12-23	1525-1527	of	abstract[86]	new[86]	_	_
12-24	1528-1531	the	abstract[86]|abstract[88]	new[86]|giv[88]	_	_
12-25	1532-1544	intervention	abstract[86]|event|abstract[88]	new[86]|giv|giv[88]	_	_
12-26	1545-1551	period	abstract[86]|abstract[88]	new[86]|giv[88]	_	_
12-27	1552-1553	.	_	_	_	_

#Text=Hence , periodic fasting can significantly reduce weight , and this effect can be maintained over time .
13-1	1554-1559	Hence	_	_	_	_
13-2	1560-1561	,	_	_	_	_
13-3	1562-1570	periodic	abstract[89]	giv[89]	coref	14-10[0_89]
13-4	1571-1578	fasting	abstract[89]	giv[89]	_	_
13-5	1579-1582	can	_	_	_	_
13-6	1583-1596	significantly	_	_	_	_
13-7	1597-1603	reduce	_	_	_	_
13-8	1604-1610	weight	abstract	giv	coref	20-10
13-9	1611-1612	,	_	_	_	_
13-10	1613-1616	and	_	_	_	_
13-11	1617-1621	this	abstract[91]	new[91]	_	_
13-12	1622-1628	effect	abstract[91]	new[91]	_	_
13-13	1629-1632	can	_	_	_	_
13-14	1633-1635	be	_	_	_	_
13-15	1636-1646	maintained	_	_	_	_
13-16	1647-1651	over	_	_	_	_
13-17	1652-1656	time	_	_	_	_
13-18	1657-1658	.	_	_	_	_

#Text=There are several concerns about the adverse effects of fasting .
14-1	1659-1664	There	_	_	_	_
14-2	1665-1668	are	_	_	_	_
14-3	1669-1676	several	abstract[92]	new[92]	_	_
14-4	1677-1685	concerns	abstract[92]	new[92]	_	_
14-5	1686-1691	about	abstract[92]	new[92]	_	_
14-6	1692-1695	the	abstract[92]|abstract[93]	new[92]|new[93]	coref	16-37[114_93]
14-7	1696-1703	adverse	abstract[92]|abstract[93]	new[92]|new[93]	_	_
14-8	1704-1711	effects	abstract[92]|abstract[93]	new[92]|new[93]	_	_
14-9	1712-1714	of	abstract[92]|abstract[93]	new[92]|new[93]	_	_
14-10	1715-1722	fasting	abstract[92]|abstract[93]|abstract	new[92]|new[93]|giv	coref	16-18[107_0]
14-11	1723-1724	.	_	_	_	_

#Text=Several non-fatal ( e. g. , headache ) and rarely fatal ( e. g. , ventricular arrhythmia ) events have been reported .
15-1	1725-1732	Several	abstract[95]	new[95]	appos	15-4[96_95]
15-2	1733-1742	non-fatal	abstract[95]	new[95]	_	_
15-3	1743-1744	(	_	_	_	_
15-4	1745-1747	e.	abstract[96]	giv[96]	coref	24-10[167_96]
15-5	1748-1750	g.	abstract[96]|abstract	giv[96]|new	appos	15-7
15-6	1751-1752	,	_	_	_	_
15-7	1753-1761	headache	abstract	giv	_	_
15-8	1762-1763	)	_	_	_	_
15-9	1764-1767	and	_	_	_	_
15-10	1768-1774	rarely	_	_	_	_
15-11	1775-1780	fatal	_	_	_	_
15-12	1781-1782	(	_	_	_	_
15-13	1783-1785	e.	abstract	new	_	_
15-14	1786-1788	g.	_	_	_	_
15-15	1789-1790	,	_	_	_	_
15-16	1791-1802	ventricular	abstract|abstract[101]	new|new[101]	_	_
15-17	1803-1813	arrhythmia	abstract[101]	new[101]	_	_
15-18	1814-1815	)	_	_	_	_
15-19	1816-1822	events	event	new	coref	16-4[104_0]
15-20	1823-1827	have	_	_	_	_
15-21	1828-1832	been	_	_	_	_
15-22	1833-1841	reported	_	_	_	_
15-23	1842-1843	.	_	_	_	_

#Text=In contrast , no severe adverse events were found in a cohort of 1422 subjects treated with a periodic fasting lasting 4 – 21 days , . Michalsen et al. evaluated the acceptance , safety , effects on health-related outcomes , and lifestyle adherence of fasting therapy in different chronic internal diseases .
16-1	1844-1846	In	_	_	_	_
16-2	1847-1855	contrast	abstract	giv	_	_
16-3	1856-1857	,	_	_	_	_
16-4	1858-1860	no	event[104]	giv[104]	coref	17-3[121_104]
16-5	1861-1867	severe	event[104]	giv[104]	_	_
16-6	1868-1875	adverse	event[104]	giv[104]	_	_
16-7	1876-1882	events	event[104]	giv[104]	_	_
16-8	1883-1887	were	_	_	_	_
16-9	1888-1893	found	_	_	_	_
16-10	1894-1896	in	_	_	_	_
16-11	1897-1898	a	person[105]	new[105]	_	_
16-12	1899-1905	cohort	person[105]	new[105]	_	_
16-13	1906-1908	of	person[105]	new[105]	_	_
16-14	1909-1913	1422	person[105]|person[106]	new[105]|giv[106]	ana	17-1[0_106]
16-15	1914-1922	subjects	person[105]|person[106]	new[105]|giv[106]	_	_
16-16	1923-1930	treated	_	_	_	_
16-17	1931-1935	with	_	_	_	_
16-18	1936-1937	a	abstract[107]	giv[107]	coref	22-5[152_107]
16-19	1938-1946	periodic	abstract[107]	giv[107]	_	_
16-20	1947-1954	fasting	abstract[107]	giv[107]	_	_
16-21	1955-1962	lasting	_	_	_	_
16-22	1963-1964	4	time[108]	giv[108]	coref	27-7[196_108]
16-23	1965-1966	–	time[108]	giv[108]	_	_
16-24	1967-1969	21	time[108]|quantity	giv[108]|new	_	_
16-25	1970-1974	days	time	new	_	_
16-26	1975-1976	,	_	_	_	_
16-27	1977-1978	.	_	_	_	_
16-28	1979-1988	Michalsen	person	new	_	_
16-29	1989-1991	et	_	_	_	_
16-30	1992-1995	al.	_	_	_	_
16-31	1996-2005	evaluated	_	_	_	_
16-32	2006-2009	the	abstract[112]	new[112]	_	_
16-33	2010-2020	acceptance	abstract[112]	new[112]	_	_
16-34	2021-2022	,	_	_	_	_
16-35	2023-2029	safety	abstract	new	_	_
16-36	2030-2031	,	_	_	_	_
16-37	2032-2039	effects	abstract[114]	giv[114]	_	_
16-38	2040-2042	on	abstract[114]	giv[114]	_	_
16-39	2043-2057	health-related	abstract[114]|abstract[115]	giv[114]|giv[115]	_	_
16-40	2058-2066	outcomes	abstract[114]|abstract[115]	giv[114]|giv[115]	_	_
16-41	2067-2068	,	_	_	_	_
16-42	2069-2072	and	_	_	_	_
16-43	2073-2082	lifestyle	abstract|event[117]	giv|giv[117]	_	_
16-44	2083-2092	adherence	event[117]	giv[117]	_	_
16-45	2093-2095	of	_	_	_	_
16-46	2096-2103	fasting	_	_	_	_
16-47	2104-2111	therapy	abstract	new	coref	18-7[127_0]
16-48	2112-2114	in	_	_	_	_
16-49	2115-2124	different	abstract[119]	new[119]	_	_
16-50	2125-2132	chronic	abstract[119]	new[119]	_	_
16-51	2133-2141	internal	abstract[119]	new[119]	_	_
16-52	2142-2150	diseases	abstract[119]	new[119]	_	_
16-53	2151-2152	.	_	_	_	_

#Text=They found no serious adverse events throughout their study .
17-1	2153-2157	They	person	giv	ana	17-8
17-2	2158-2163	found	_	_	_	_
17-3	2164-2166	no	event[121]	giv[121]	_	_
17-4	2167-2174	serious	event[121]	giv[121]	_	_
17-5	2175-2182	adverse	event[121]	giv[121]	_	_
17-6	2183-2189	events	event[121]	giv[121]	_	_
17-7	2190-2200	throughout	_	_	_	_
17-8	2201-2206	their	person|abstract[123]	giv|giv[123]	coref|coref	18-1[125_123]|18-1[125_123]
17-9	2207-2212	study	abstract[123]	giv[123]	_	_
17-10	2213-2214	.	_	_	_	_

#Text=Our study supports the hypothesis that fasting therapy provided in a controlled clinical setting is a safe intervention .
18-1	2215-2218	Our	person|abstract[125]	giv|giv[125]	ana|coref|ana|coref	29-1|38-13[271_125]|29-1|38-13[271_125]
18-2	2219-2224	study	abstract[125]	giv[125]	_	_
18-3	2225-2233	supports	_	_	_	_
18-4	2234-2237	the	abstract[126]	giv[126]	_	_
18-5	2238-2248	hypothesis	abstract[126]	giv[126]	_	_
18-6	2249-2253	that	_	_	_	_
18-7	2254-2261	fasting	event[127]	giv[127]	coref	18-16[129_127]
18-8	2262-2269	therapy	event[127]	giv[127]	_	_
18-9	2270-2278	provided	_	_	_	_
18-10	2279-2281	in	_	_	_	_
18-11	2282-2283	a	abstract[128]	new[128]	_	_
18-12	2284-2294	controlled	abstract[128]	new[128]	_	_
18-13	2295-2303	clinical	abstract[128]	new[128]	_	_
18-14	2304-2311	setting	abstract[128]	new[128]	_	_
18-15	2312-2314	is	_	_	_	_
18-16	2315-2316	a	event[129]	giv[129]	coref	32-4[228_129]
18-17	2317-2321	safe	event[129]	giv[129]	_	_
18-18	2322-2334	intervention	event[129]	giv[129]	_	_
18-19	2335-2336	.	_	_	_	_

#Text=There is a large body of evidence on the beneficial effects of carbohydrate restriction and hypocaloric diets on NAFLD .
19-1	2337-2342	There	_	_	_	_
19-2	2343-2345	is	_	_	_	_
19-3	2346-2347	a	object[130]	giv[130]	_	_
19-4	2348-2353	large	object[130]	giv[130]	_	_
19-5	2354-2358	body	object[130]	giv[130]	_	_
19-6	2359-2361	of	object[130]	giv[130]	_	_
19-7	2362-2370	evidence	object[130]|abstract[131]	giv[130]|giv[131]	ana	20-1[0_131]
19-8	2371-2373	on	object[130]|abstract[131]	giv[130]|giv[131]	_	_
19-9	2374-2377	the	object[130]|abstract[131]|abstract[132]	giv[130]|giv[131]|new[132]	coref	23-4[158_132]
19-10	2378-2388	beneficial	object[130]|abstract[131]|abstract[132]	giv[130]|giv[131]|new[132]	_	_
19-11	2389-2396	effects	object[130]|abstract[131]|abstract[132]	giv[130]|giv[131]|new[132]	_	_
19-12	2397-2399	of	object[130]|abstract[131]|abstract[132]	giv[130]|giv[131]|new[132]	_	_
19-13	2400-2412	carbohydrate	object[130]|abstract[131]|abstract[132]|abstract|abstract[134]	giv[130]|giv[131]|new[132]|new|new[134]	coref|coref|coref|coref	21-5|21-5[147_134]|21-5|21-5[147_134]
19-14	2413-2424	restriction	object[130]|abstract[131]|abstract[132]|abstract[134]	giv[130]|giv[131]|new[132]|new[134]	_	_
19-15	2425-2428	and	object[130]|abstract[131]|abstract[132]	giv[130]|giv[131]|new[132]	_	_
19-16	2429-2440	hypocaloric	object[130]|abstract[131]|abstract[132]|abstract[135]	giv[130]|giv[131]|new[132]|new[135]	_	_
19-17	2441-2446	diets	object[130]|abstract[131]|abstract[132]|abstract[135]	giv[130]|giv[131]|new[132]|new[135]	_	_
19-18	2447-2449	on	object[130]|abstract[131]|abstract[132]|abstract[135]	giv[130]|giv[131]|new[132]|new[135]	_	_
19-19	2450-2455	NAFLD	object[130]|abstract[131]|abstract[132]|abstract[135]|substance	giv[130]|giv[131]|new[132]|new[135]|giv	coref	28-28
19-20	2456-2457	.	_	_	_	_

#Text=It has also been shown that-at equal levels of weight reduction-a carbohydrate-restricted diet leads to a significantly greater intrahepatic triglyceride reduction than low-calorie diet alone .
20-1	2458-2460	It	abstract	giv	coref	28-4[202_0]
20-2	2461-2464	has	_	_	_	_
20-3	2465-2469	also	_	_	_	_
20-4	2470-2474	been	_	_	_	_
20-5	2475-2480	shown	_	_	_	_
20-6	2481-2488	that-at	_	_	_	_
20-7	2489-2494	equal	abstract[138]	new[138]	coref	32-22[233_138]
20-8	2495-2501	levels	abstract[138]	new[138]	_	_
20-9	2502-2504	of	abstract[138]	new[138]	_	_
20-10	2505-2511	weight	abstract[138]|abstract	new[138]|giv	coref	23-5
20-11	2512-2523	reduction-a	event[140]	new[140]	coref	20-23[143_140]
20-12	2524-2547	carbohydrate-restricted	event[140]	new[140]	_	_
20-13	2548-2552	diet	event[140]	new[140]	_	_
20-14	2553-2558	leads	_	_	_	_
20-15	2559-2561	to	_	_	_	_
20-16	2562-2563	a	abstract[142]	giv[142]	_	_
20-17	2564-2577	significantly	abstract[142]	giv[142]	_	_
20-18	2578-2585	greater	abstract[142]	giv[142]	_	_
20-19	2586-2598	intrahepatic	abstract[142]	giv[142]	_	_
20-20	2599-2611	triglyceride	abstract|abstract[142]	new|giv[142]	_	_
20-21	2612-2621	reduction	abstract[142]	giv[142]	_	_
20-22	2622-2626	than	abstract[142]	giv[142]	_	_
20-23	2627-2638	low-calorie	abstract[142]|event[143]	giv[142]|giv[143]	_	_
20-24	2639-2643	diet	abstract[142]|event[143]	giv[142]|giv[143]	_	_
20-25	2644-2649	alone	abstract[142]|event[143]	giv[142]|giv[143]	_	_
20-26	2650-2651	.	_	_	_	_

#Text=The metabolic advantage of carbohydrate restriction appears to be related to a more pronounced lipid oxidation and enhanced ketogenesis .
21-1	2652-2655	The	abstract[145]	new[145]	_	_
21-2	2656-2665	metabolic	person|abstract[145]	giv|new[145]	coref	23-15
21-3	2666-2675	advantage	abstract[145]	new[145]	_	_
21-4	2676-2678	of	abstract[145]	new[145]	_	_
21-5	2679-2691	carbohydrate	abstract[145]|abstract|abstract[147]	new[145]|giv|giv[147]	coref|coref	22-16[155_147]|22-16[155_147]
21-6	2692-2703	restriction	abstract[145]|abstract[147]	new[145]|giv[147]	_	_
21-7	2704-2711	appears	_	_	_	_
21-8	2712-2714	to	_	_	_	_
21-9	2715-2717	be	_	_	_	_
21-10	2718-2725	related	_	_	_	_
21-11	2726-2728	to	_	_	_	_
21-12	2729-2730	a	abstract[149]	new[149]	_	_
21-13	2731-2735	more	abstract[149]	new[149]	_	_
21-14	2736-2746	pronounced	abstract[149]	new[149]	_	_
21-15	2747-2752	lipid	person|abstract[149]	new|new[149]	coref	23-22
21-16	2753-2762	oxidation	abstract[149]	new[149]	_	_
21-17	2763-2766	and	_	_	_	_
21-18	2767-2775	enhanced	substance[150]	new[150]	coref	27-3[0_150]
21-19	2776-2787	ketogenesis	substance[150]	new[150]	_	_
21-20	2788-2789	.	_	_	_	_

#Text=In recent years , intermittent and periodic fasting has gained popularity as an alternative to continuous caloric restriction .
22-1	2790-2792	In	_	_	_	_
22-2	2793-2799	recent	time[151]	new[151]	_	_
22-3	2800-2805	years	time[151]	new[151]	_	_
22-4	2806-2807	,	_	_	_	_
22-5	2808-2820	intermittent	abstract[152]	giv[152]	coref	23-9[159_152]
22-6	2821-2824	and	abstract[152]	giv[152]	_	_
22-7	2825-2833	periodic	abstract[152]	giv[152]	_	_
22-8	2834-2841	fasting	abstract[152]	giv[152]	_	_
22-9	2842-2845	has	_	_	_	_
22-10	2846-2852	gained	_	_	_	_
22-11	2853-2863	popularity	abstract	new	_	_
22-12	2864-2866	as	_	_	_	_
22-13	2867-2869	an	_	_	_	_
22-14	2870-2881	alternative	_	_	_	_
22-15	2882-2884	to	_	_	_	_
22-16	2885-2895	continuous	abstract[155]	giv[155]	_	_
22-17	2896-2903	caloric	abstract|abstract[155]	new|giv[155]	_	_
22-18	2904-2915	restriction	abstract[155]	giv[155]	_	_
22-19	2916-2917	.	_	_	_	_

#Text=In addition to the weight loss effects , periodic fasting is associated with several metabolic benefits , including the improvement of lipid profiles .
23-1	2918-2920	In	_	_	_	_
23-2	2921-2929	addition	_	_	_	_
23-3	2930-2932	to	_	_	_	_
23-4	2933-2936	the	abstract[158]	giv[158]	coref	25-8[171_158]
23-5	2937-2943	weight	abstract|abstract[158]	giv|giv[158]	_	_
23-6	2944-2948	loss	abstract|abstract[158]	giv|giv[158]	_	_
23-7	2949-2956	effects	abstract[158]	giv[158]	_	_
23-8	2957-2958	,	_	_	_	_
23-9	2959-2967	periodic	abstract[159]	giv[159]	coref	24-7[166_159]
23-10	2968-2975	fasting	abstract[159]	giv[159]	_	_
23-11	2976-2978	is	_	_	_	_
23-12	2979-2989	associated	_	_	_	_
23-13	2990-2994	with	_	_	_	_
23-14	2995-3002	several	abstract[161]	new[161]	_	_
23-15	3003-3012	metabolic	person|abstract[161]	giv|new[161]	coref	25-13
23-16	3013-3021	benefits	abstract[161]	new[161]	_	_
23-17	3022-3023	,	_	_	_	_
23-18	3024-3033	including	_	_	_	_
23-19	3034-3037	the	abstract[162]	new[162]	ana	24-1[0_162]
23-20	3038-3049	improvement	abstract[162]	new[162]	_	_
23-21	3050-3052	of	abstract[162]	new[162]	_	_
23-22	3053-3058	lipid	abstract[162]|person|abstract[164]	new[162]|giv|new[164]	_	_
23-23	3059-3067	profiles	abstract[162]|abstract[164]	new[162]|new[164]	_	_
23-24	3068-3069	.	_	_	_	_

#Text=This has been also shown for intermittent fasting , e. g. , Ramadan fasting .
24-1	3070-3074	This	abstract	giv	_	_
24-2	3075-3078	has	_	_	_	_
24-3	3079-3083	been	_	_	_	_
24-4	3084-3088	also	_	_	_	_
24-5	3089-3094	shown	_	_	_	_
24-6	3095-3098	for	_	_	_	_
24-7	3099-3111	intermittent	abstract[166]	giv[166]	coref	24-13[169_166]
24-8	3112-3119	fasting	abstract[166]	giv[166]	_	_
24-9	3120-3121	,	_	_	_	_
24-10	3122-3124	e.	abstract[167]	giv[167]	coref	38-45[281_167]
24-11	3125-3127	g.	abstract[167]	giv[167]	_	_
24-12	3128-3129	,	_	_	_	_
24-13	3130-3137	Ramadan	person|abstract[169]	new|giv[169]	coref|coref	29-7[215_169]|29-7[215_169]
24-14	3138-3145	fasting	abstract[169]	giv[169]	_	_
24-15	3146-3147	.	_	_	_	_

#Text=The key mechanism responsible for many of these beneficial effects is the metabolic switch from the utilization of glycogenolysis-derived glucose to fatty acids and fatty acid-derived ketones , i. e. , a fundamental switch from lipid synthesis and fat storage to mobilization of fat in the form of free fatty acids and fatty acid-derived ketones .
25-1	3148-3151	The	object[170]	new[170]	coref	25-12[173_170]
25-2	3152-3155	key	object[170]	new[170]	_	_
25-3	3156-3165	mechanism	object[170]	new[170]	_	_
25-4	3166-3177	responsible	object[170]	new[170]	_	_
25-5	3178-3181	for	_	_	_	_
25-6	3182-3186	many	_	_	_	_
25-7	3187-3189	of	_	_	_	_
25-8	3190-3195	these	abstract[171]	giv[171]	_	_
25-9	3196-3206	beneficial	abstract[171]	giv[171]	_	_
25-10	3207-3214	effects	abstract[171]	giv[171]	_	_
25-11	3215-3217	is	_	_	_	_
25-12	3218-3221	the	object[173]	giv[173]	_	_
25-13	3222-3231	metabolic	person|object[173]	giv|giv[173]	_	_
25-14	3232-3238	switch	object[173]	giv[173]	_	_
25-15	3239-3243	from	object[173]	giv[173]	_	_
25-16	3244-3247	the	object[173]|abstract[174]	giv[173]|new[174]	_	_
25-17	3248-3259	utilization	object[173]|abstract[174]	giv[173]|new[174]	_	_
25-18	3260-3262	of	object[173]|abstract[174]	giv[173]|new[174]	_	_
25-19	3263-3285	glycogenolysis-derived	object[173]|abstract[174]|substance[175]	giv[173]|new[174]|new[175]	_	_
25-20	3286-3293	glucose	object[173]|abstract[174]|substance[175]	giv[173]|new[174]|new[175]	_	_
25-21	3294-3296	to	object[173]|abstract[174]	giv[173]|new[174]	_	_
25-22	3297-3302	fatty	object[173]|abstract[174]|substance[176]|substance[177]	giv[173]|new[174]|new[176]|new[177]	coref|coref|coref|coref	25-49[186_176]|25-49[187_177]|25-49[186_176]|25-49[187_177]
25-23	3303-3308	acids	object[173]|abstract[174]|substance[176]|substance[177]	giv[173]|new[174]|new[176]|new[177]	_	_
25-24	3309-3312	and	object[173]|abstract[174]|substance[177]	giv[173]|new[174]|new[177]	_	_
25-25	3313-3318	fatty	object[173]|abstract[174]|substance[177]|substance[178]	giv[173]|new[174]|new[177]|new[178]	coref	25-53[188_178]
25-26	3319-3331	acid-derived	object[173]|abstract[174]|substance[177]|substance[178]	giv[173]|new[174]|new[177]|new[178]	_	_
25-27	3332-3339	ketones	object[173]|abstract[174]|substance[177]|substance[178]	giv[173]|new[174]|new[177]|new[178]	_	_
25-28	3340-3341	,	object[173]	giv[173]	_	_
25-29	3342-3344	i.	object[173]	giv[173]	_	_
25-30	3345-3347	e.	object[173]	giv[173]	_	_
25-31	3348-3349	,	object[173]	giv[173]	_	_
25-32	3350-3351	a	object[173]	giv[173]	_	_
25-33	3352-3363	fundamental	object[173]	giv[173]	_	_
25-34	3364-3370	switch	object[173]	giv[173]	_	_
25-35	3371-3375	from	object[173]	giv[173]	_	_
25-36	3376-3381	lipid	object[173]|abstract|abstract[180]	giv[173]|new|new[180]	coref|coref	41-22|41-22
25-37	3382-3391	synthesis	object[173]|abstract[180]	giv[173]|new[180]	_	_
25-38	3392-3395	and	object[173]	giv[173]	_	_
25-39	3396-3399	fat	object[173]|substance|abstract[182]	giv[173]|new|new[182]	coref|coref	25-44[184_0]|25-44[184_0]
25-40	3400-3407	storage	object[173]|abstract[182]	giv[173]|new[182]	_	_
25-41	3408-3410	to	object[173]	giv[173]	_	_
25-42	3411-3423	mobilization	object[173]|abstract[183]	giv[173]|new[183]	_	_
25-43	3424-3426	of	object[173]|abstract[183]	giv[173]|new[183]	_	_
25-44	3427-3430	fat	object[173]|abstract[183]|substance[184]	giv[173]|new[183]|giv[184]	coref	29-14[218_184]
25-45	3431-3433	in	object[173]|abstract[183]|substance[184]	giv[173]|new[183]|giv[184]	_	_
25-46	3434-3437	the	object[173]|abstract[183]|substance[184]|abstract[185]	giv[173]|new[183]|giv[184]|new[185]	ana	26-1[0_185]
25-47	3438-3442	form	object[173]|abstract[183]|substance[184]|abstract[185]	giv[173]|new[183]|giv[184]|new[185]	_	_
25-48	3443-3445	of	object[173]|abstract[183]|substance[184]|abstract[185]	giv[173]|new[183]|giv[184]|new[185]	_	_
25-49	3446-3450	free	object[173]|abstract[183]|substance[184]|abstract[185]|substance[186]|substance[187]	giv[173]|new[183]|giv[184]|new[185]|giv[186]|giv[187]	_	_
25-50	3451-3456	fatty	object[173]|abstract[183]|substance[184]|abstract[185]|substance[186]|substance[187]	giv[173]|new[183]|giv[184]|new[185]|giv[186]|giv[187]	_	_
25-51	3457-3462	acids	object[173]|abstract[183]|substance[184]|abstract[185]|substance[186]|substance[187]	giv[173]|new[183]|giv[184]|new[185]|giv[186]|giv[187]	_	_
25-52	3463-3466	and	object[173]|abstract[183]|substance[184]|abstract[185]|substance[187]	giv[173]|new[183]|giv[184]|new[185]|giv[187]	_	_
25-53	3467-3472	fatty	object[173]|abstract[183]|substance[184]|abstract[185]|substance[187]|substance[188]	giv[173]|new[183]|giv[184]|new[185]|giv[187]|giv[188]	_	_
25-54	3473-3485	acid-derived	object[173]|abstract[183]|substance[184]|abstract[185]|substance[187]|substance[188]	giv[173]|new[183]|giv[184]|new[185]|giv[187]|giv[188]	_	_
25-55	3486-3493	ketones	object[173]|abstract[183]|substance[184]|abstract[185]|substance[187]|substance[188]	giv[173]|new[183]|giv[184]|new[185]|giv[187]|giv[188]	_	_
25-56	3494-3495	.	_	_	_	_

#Text=This occurs between 12 and 36 hours after cessation of food consumption .
26-1	3496-3500	This	abstract	giv	_	_
26-2	3501-3507	occurs	_	_	_	_
26-3	3508-3515	between	_	_	_	_
26-4	3516-3518	12	time[190]	new[190]	_	_
26-5	3519-3522	and	time[190]	new[190]	_	_
26-6	3523-3525	36	time[190]	new[190]	_	_
26-7	3526-3531	hours	time[190]	new[190]	_	_
26-8	3532-3537	after	_	_	_	_
26-9	3538-3547	cessation	event[191]	new[191]	_	_
26-10	3548-3550	of	event[191]	new[191]	_	_
26-11	3551-3555	food	event[191]|substance|abstract[193]	new[191]|new|new[193]	_	_
26-12	3556-3567	consumption	event[191]|abstract[193]	new[191]|new[193]	_	_
26-13	3568-3569	.	_	_	_	_

#Text=Hyperinsulinemia suppresses ketogenesis and therefore prolongs the time to switch in cases of obesity , insulin resistance , and T2DM .
27-1	3570-3586	Hyperinsulinemia	abstract	new	_	_
27-2	3587-3597	suppresses	_	_	_	_
27-3	3598-3609	ketogenesis	substance	giv	coref	28-7[203_0]
27-4	3610-3613	and	_	_	_	_
27-5	3614-3623	therefore	_	_	_	_
27-6	3624-3632	prolongs	_	_	_	_
27-7	3633-3636	the	time[196]	giv[196]	_	_
27-8	3637-3641	time	time[196]	giv[196]	_	_
27-9	3642-3644	to	_	_	_	_
27-10	3645-3651	switch	_	_	_	_
27-11	3652-3654	in	_	_	_	_
27-12	3655-3660	cases	abstract[197]	new[197]	_	_
27-13	3661-3663	of	abstract[197]	new[197]	_	_
27-14	3664-3671	obesity	abstract[197]|abstract	new[197]|giv	_	_
27-15	3672-3673	,	abstract[197]	new[197]	_	_
27-16	3674-3681	insulin	abstract[197]|event|abstract[200]	new[197]|giv|giv[200]	coref|coref|coref|coref	37-5|37-5[256_200]|37-5|37-5[256_200]
27-17	3682-3692	resistance	abstract[197]|abstract[200]	new[197]|giv[200]	_	_
27-18	3693-3694	,	abstract[197]	new[197]	_	_
27-19	3695-3698	and	abstract[197]	new[197]	_	_
27-20	3699-3703	T2DM	abstract[197]|abstract	new[197]|giv	coref	37-8
27-21	3704-3705	.	_	_	_	_

#Text=Although there is some evidence of impaired ketogenesis during the progression of liver disease to steatohepatitis , therapies that increase hepatic ketogenesis are expected nonetheless to ameliorate NAFLD .
28-1	3706-3714	Although	_	_	_	_
28-2	3715-3720	there	_	_	_	_
28-3	3721-3723	is	_	_	_	_
28-4	3724-3728	some	abstract[202]	giv[202]	coref	29-4[214_202]
28-5	3729-3737	evidence	abstract[202]	giv[202]	_	_
28-6	3738-3740	of	abstract[202]	giv[202]	_	_
28-7	3741-3749	impaired	abstract[202]|substance[203]	giv[202]|giv[203]	_	_
28-8	3750-3761	ketogenesis	abstract[202]|substance[203]	giv[202]|giv[203]	_	_
28-9	3762-3768	during	abstract[202]	giv[202]	_	_
28-10	3769-3772	the	abstract[202]|event[204]	giv[202]|new[204]	_	_
28-11	3773-3784	progression	abstract[202]|event[204]	giv[202]|new[204]	_	_
28-12	3785-3787	of	abstract[202]|event[204]	giv[202]|new[204]	_	_
28-13	3788-3793	liver	abstract[202]|event[204]|object|abstract[206]	giv[202]|new[204]|giv|new[206]	coref|coref	29-14|29-14
28-14	3794-3801	disease	abstract[202]|event[204]|abstract[206]	giv[202]|new[204]|new[206]	_	_
28-15	3802-3804	to	abstract[202]|event[204]|abstract[206]	giv[202]|new[204]|new[206]	_	_
28-16	3805-3820	steatohepatitis	abstract[202]|event[204]|abstract[206]|abstract	giv[202]|new[204]|new[206]|new	_	_
28-17	3821-3822	,	abstract[202]|event[204]|abstract[206]	giv[202]|new[204]|new[206]	_	_
28-18	3823-3832	therapies	abstract[202]|event[204]|abstract[206]|object	giv[202]|new[204]|new[206]|new	_	_
28-19	3833-3837	that	_	_	_	_
28-20	3838-3846	increase	_	_	_	_
28-21	3847-3854	hepatic	abstract|abstract[210]	new|new[210]	_	_
28-22	3855-3866	ketogenesis	abstract[210]	new[210]	_	_
28-23	3867-3870	are	_	_	_	_
28-24	3871-3879	expected	_	_	_	_
28-25	3880-3891	nonetheless	_	_	_	_
28-26	3892-3894	to	_	_	_	_
28-27	3895-3905	ameliorate	_	_	_	_
28-28	3906-3911	NAFLD	substance	giv	coref	29-28
28-29	3912-3913	.	_	_	_	_

#Text=Our data provided first evidence that periodic fasting leads to a clearance of liver fat : fasting significantly reduced FLI and increased the proportion of patients without NAFLD ( FLI < 30 units ;
29-1	3914-3917	Our	person|abstract[213]	giv|new[213]	ana|ana	38-16|38-16
29-2	3918-3922	data	abstract[213]	new[213]	_	_
29-3	3923-3931	provided	_	_	_	_
29-4	3932-3937	first	abstract[214]	giv[214]	_	_
29-5	3938-3946	evidence	abstract[214]	giv[214]	_	_
29-6	3947-3951	that	_	_	_	_
29-7	3952-3960	periodic	abstract[215]	giv[215]	coref	32-4[0_215]
29-8	3961-3968	fasting	abstract[215]	giv[215]	_	_
29-9	3969-3974	leads	_	_	_	_
29-10	3975-3977	to	_	_	_	_
29-11	3978-3979	a	abstract[216]	new[216]	_	_
29-12	3980-3989	clearance	abstract[216]	new[216]	_	_
29-13	3990-3992	of	abstract[216]	new[216]	_	_
29-14	3993-3998	liver	abstract[216]|object|substance[218]	new[216]|giv|giv[218]	coref|coref|coref|coref	34-19[243_0]|37-33[266_218]|34-19[243_0]|37-33[266_218]
29-15	3999-4002	fat	abstract[216]|substance[218]	new[216]|giv[218]	_	_
29-16	4003-4004	:	_	_	_	_
29-17	4005-4012	fasting	_	_	_	_
29-18	4013-4026	significantly	_	_	_	_
29-19	4027-4034	reduced	_	_	_	_
29-20	4035-4038	FLI	abstract	giv	coref	29-30
29-21	4039-4042	and	_	_	_	_
29-22	4043-4052	increased	_	_	_	_
29-23	4053-4056	the	abstract[220]	new[220]	_	_
29-24	4057-4067	proportion	abstract[220]	new[220]	_	_
29-25	4068-4070	of	abstract[220]	new[220]	_	_
29-26	4071-4079	patients	abstract[220]|person[221]	new[220]|giv[221]	coref	38-1[267_221]
29-27	4080-4087	without	abstract[220]|person[221]	new[220]|giv[221]	_	_
29-28	4088-4093	NAFLD	abstract[220]|person[221]|quantity	new[220]|giv[221]|giv	coref	36-15
29-29	4094-4095	(	_	_	_	_
29-30	4096-4099	FLI	abstract	giv	coref	32-14[232_0]
29-31	4100-4101	<	_	_	_	_
29-32	4102-4104	30	quantity[224]	new[224]	_	_
29-33	4105-4110	units	quantity[224]	new[224]	_	_
29-34	4111-4112	;	_	_	_	_

#Text=Figure 2
30-1	4113-4119	Figure	abstract[225]	new[225]	_	_
30-2	4120-4121	2	abstract[225]	new[225]	_	_

#Text=) .
31-1	4122-4123	)	_	_	_	_
31-2	4124-4125	.	_	_	_	_

#Text=The effects of fasting therapy were stronger in males and in individuals with higher baseline FLI , higher GOT , and higher cholesterol levels .
32-1	4126-4129	The	abstract[226]	new[226]	_	_
32-2	4130-4137	effects	abstract[226]	new[226]	_	_
32-3	4138-4140	of	abstract[226]	new[226]	_	_
32-4	4141-4148	fasting	abstract[226]|abstract|abstract[228]	new[226]|giv|giv[228]	coref|coref|coref|coref	33-3|38-20[274_228]|33-3|38-20[274_228]
32-5	4149-4156	therapy	abstract[226]|abstract[228]	new[226]|giv[228]	_	_
32-6	4157-4161	were	_	_	_	_
32-7	4162-4170	stronger	_	_	_	_
32-8	4171-4173	in	_	_	_	_
32-9	4174-4179	males	person	new	_	_
32-10	4180-4183	and	_	_	_	_
32-11	4184-4186	in	_	_	_	_
32-12	4187-4198	individuals	person[230]	new[230]	_	_
32-13	4199-4203	with	person[230]	new[230]	_	_
32-14	4204-4210	higher	person[230]|abstract[232]	new[230]|giv[232]	coref	33-7[236_232]
32-15	4211-4219	baseline	person[230]|abstract|abstract[232]	new[230]|new|giv[232]	_	_
32-16	4220-4223	FLI	person[230]|abstract[232]	new[230]|giv[232]	_	_
32-17	4224-4225	,	_	_	_	_
32-18	4226-4232	higher	_	_	_	_
32-19	4233-4236	GOT	_	_	_	_
32-20	4237-4238	,	_	_	_	_
32-21	4239-4242	and	_	_	_	_
32-22	4243-4249	higher	abstract[233]	giv[233]	coref	40-8[293_233]
32-23	4250-4261	cholesterol	abstract[233]	giv[233]	_	_
32-24	4262-4268	levels	abstract[233]	giv[233]	_	_
32-25	4269-4270	.	_	_	_	_

#Text=Each additional fasting day further decreased the FLI .
33-1	4271-4275	Each	time[235]	new[235]	_	_
33-2	4276-4286	additional	time[235]	new[235]	_	_
33-3	4287-4294	fasting	abstract|time[235]	giv|new[235]	coref	34-10
33-4	4295-4298	day	time[235]	new[235]	_	_
33-5	4299-4306	further	_	_	_	_
33-6	4307-4316	decreased	_	_	_	_
33-7	4317-4320	the	abstract[236]	giv[236]	coref	34-24[244_236]
33-8	4321-4324	FLI	abstract[236]	giv[236]	_	_
33-9	4325-4326	.	_	_	_	_

#Text=The binary logistic regression showed that every day of fasting increase by 40 % the chance to improve a manifest fatty liver ( FLI > 60 ) and switch to a lower category of risk .
34-1	4327-4330	The	abstract[237]	new[237]	_	_
34-2	4331-4337	binary	abstract[237]	new[237]	_	_
34-3	4338-4346	logistic	abstract[237]	new[237]	_	_
34-4	4347-4357	regression	abstract[237]	new[237]	_	_
34-5	4358-4364	showed	_	_	_	_
34-6	4365-4369	that	_	_	_	_
34-7	4370-4375	every	_	_	_	_
34-8	4376-4379	day	_	_	_	_
34-9	4380-4382	of	_	_	_	_
34-10	4383-4390	fasting	abstract|abstract[239]	giv|new[239]	coref|coref	35-7|35-7
34-11	4391-4399	increase	abstract[239]	new[239]	_	_
34-12	4400-4402	by	abstract[239]	new[239]	_	_
34-13	4403-4405	40	abstract[239]|quantity[240]	new[239]|new[240]	_	_
34-14	4406-4407	%	abstract[239]|quantity[240]	new[239]|new[240]	_	_
34-15	4408-4411	the	abstract[241]	new[241]	_	_
34-16	4412-4418	chance	abstract[241]	new[241]	_	_
34-17	4419-4421	to	_	_	_	_
34-18	4422-4429	improve	abstract	new	coref	38-39[279_0]
34-19	4430-4431	a	object[243]	giv[243]	coref	35-13[250_243]
34-20	4432-4440	manifest	object[243]	giv[243]	_	_
34-21	4441-4446	fatty	animal|object[243]	new|giv[243]	_	_
34-22	4447-4452	liver	object[243]	giv[243]	_	_
34-23	4453-4454	(	_	_	_	_
34-24	4455-4458	FLI	abstract[244]	giv[244]	coref	38-8[0_244]
34-25	4459-4460	>	abstract[244]	giv[244]	_	_
34-26	4461-4463	60	abstract[244]	giv[244]	_	_
34-27	4464-4465	)	_	_	_	_
34-28	4466-4469	and	_	_	_	_
34-29	4470-4476	switch	_	_	_	_
34-30	4477-4479	to	_	_	_	_
34-31	4480-4481	a	abstract[245]	new[245]	_	_
34-32	4482-4487	lower	abstract[245]	new[245]	_	_
34-33	4488-4496	category	abstract[245]	new[245]	_	_
34-34	4497-4499	of	abstract[245]	new[245]	_	_
34-35	4500-4504	risk	abstract[245]|abstract	new[245]|new	ana	35-1
34-36	4505-4506	.	_	_	_	_

#Text=This implies that the duration of fasting must be sufficient to influence fatty liver positively .
35-1	4507-4511	This	abstract	giv	ana	36-1
35-2	4512-4519	implies	_	_	_	_
35-3	4520-4524	that	_	_	_	_
35-4	4525-4528	the	abstract[248]	new[248]	_	_
35-5	4529-4537	duration	abstract[248]	new[248]	_	_
35-6	4538-4540	of	abstract[248]	new[248]	_	_
35-7	4541-4548	fasting	abstract[248]|abstract	new[248]|giv	coref	36-8[253_0]
35-8	4549-4553	must	_	_	_	_
35-9	4554-4556	be	_	_	_	_
35-10	4557-4567	sufficient	_	_	_	_
35-11	4568-4570	to	_	_	_	_
35-12	4571-4580	influence	_	_	_	_
35-13	4581-4586	fatty	object[250]	giv[250]	coref	37-33[0_250]
35-14	4587-4592	liver	object[250]	giv[250]	_	_
35-15	4593-4603	positively	_	_	_	_
35-16	4604-4605	.	_	_	_	_

#Text=This should be taken into account when periodic fasting is considered as treatment for NAFLD .
36-1	4606-4610	This	abstract	giv	_	_
36-2	4611-4617	should	_	_	_	_
36-3	4618-4620	be	_	_	_	_
36-4	4621-4626	taken	_	_	_	_
36-5	4627-4631	into	_	_	_	_
36-6	4632-4639	account	abstract	new	_	_
36-7	4640-4644	when	_	_	_	_
36-8	4645-4653	periodic	abstract[253]	giv[253]	coref	38-21[0_253]
36-9	4654-4661	fasting	abstract[253]	giv[253]	_	_
36-10	4662-4664	is	_	_	_	_
36-11	4665-4675	considered	_	_	_	_
36-12	4676-4678	as	_	_	_	_
36-13	4679-4688	treatment	_	_	_	_
36-14	4689-4692	for	_	_	_	_
36-15	4693-4698	NAFLD	abstract	giv	coref	37-14
36-16	4699-4700	.	_	_	_	_

#Text=As already mentioned , insulin resistance , T2DM , and the development of NAFLD are closely associated conditions . Taylor et al. have shown that remission of T2DM requires a decrease of liver fat .
37-1	4701-4703	As	_	_	_	_
37-2	4704-4711	already	_	_	_	_
37-3	4712-4721	mentioned	_	_	_	_
37-4	4722-4723	,	_	_	_	_
37-5	4724-4731	insulin	event|abstract[256]	giv|giv[256]	coref|coref|coref|coref	40-4|40-4[292_256]|40-4|40-4[292_256]
37-6	4732-4742	resistance	abstract[256]	giv[256]	_	_
37-7	4743-4744	,	_	_	_	_
37-8	4745-4749	T2DM	event	giv	coref	37-28
37-9	4750-4751	,	_	_	_	_
37-10	4752-4755	and	_	_	_	_
37-11	4756-4759	the	event[258]	new[258]	_	_
37-12	4760-4771	development	event[258]	new[258]	_	_
37-13	4772-4774	of	event[258]	new[258]	_	_
37-14	4775-4780	NAFLD	event[258]|abstract	new[258]|giv	coref	40-13
37-15	4781-4784	are	_	_	_	_
37-16	4785-4792	closely	_	_	_	_
37-17	4793-4803	associated	_	_	_	_
37-18	4804-4814	conditions	abstract	new	_	_
37-19	4815-4816	.	_	_	_	_
37-20	4817-4823	Taylor	person	new	_	_
37-21	4824-4826	et	_	_	_	_
37-22	4827-4830	al.	_	_	_	_
37-23	4831-4835	have	_	_	_	_
37-24	4836-4841	shown	_	_	_	_
37-25	4842-4846	that	_	_	_	_
37-26	4847-4856	remission	event[262]	new[262]	_	_
37-27	4857-4859	of	event[262]	new[262]	_	_
37-28	4860-4864	T2DM	event[262]|event	new[262]|giv	coref	38-3
37-29	4865-4873	requires	_	_	_	_
37-30	4874-4875	a	abstract[264]	new[264]	_	_
37-31	4876-4884	decrease	abstract[264]	new[264]	_	_
37-32	4885-4887	of	abstract[264]	new[264]	_	_
37-33	4888-4893	liver	abstract[264]|object|substance[266]	new[264]|giv|giv[266]	coref|coref	40-1|40-1
37-34	4894-4897	fat	abstract[264]|substance[266]	new[264]|giv[266]	_	_
37-35	4898-4899	.	_	_	_	_

#Text=Patients with T2DM tend to have higher FLI scores , but in this study , we could demonstrate that the fasting intervention was equally effective in T2DM patients and in non-diabetic subjects in terms of FLI , although the improvement of other parameters ( e. g. , HDL , LDL , and AP ) was not as complete .
38-1	4900-4908	Patients	person[267]	giv[267]	coref	38-27[276_267]
38-2	4909-4913	with	person[267]	giv[267]	_	_
38-3	4914-4918	T2DM	person[267]|abstract	giv[267]|giv	coref	38-27
38-4	4919-4923	tend	_	_	_	_
38-5	4924-4926	to	_	_	_	_
38-6	4927-4931	have	_	_	_	_
38-7	4932-4938	higher	abstract[270]	new[270]	_	_
38-8	4939-4942	FLI	abstract|abstract[270]	giv|new[270]	coref	38-36
38-9	4943-4949	scores	abstract[270]	new[270]	_	_
38-10	4950-4951	,	_	_	_	_
38-11	4952-4955	but	_	_	_	_
38-12	4956-4958	in	_	_	_	_
38-13	4959-4963	this	abstract[271]	giv[271]	coref	39-7[286_271]
38-14	4964-4969	study	abstract[271]	giv[271]	_	_
38-15	4970-4971	,	_	_	_	_
38-16	4972-4974	we	person	giv	ana	41-1
38-17	4975-4980	could	_	_	_	_
38-18	4981-4992	demonstrate	_	_	_	_
38-19	4993-4997	that	_	_	_	_
38-20	4998-5001	the	event[274]	giv[274]	coref	41-29[0_274]
38-21	5002-5009	fasting	abstract|event[274]	giv|giv[274]	coref	39-11[287_0]
38-22	5010-5022	intervention	event[274]	giv[274]	_	_
38-23	5023-5026	was	_	_	_	_
38-24	5027-5034	equally	_	_	_	_
38-25	5035-5044	effective	_	_	_	_
38-26	5045-5047	in	_	_	_	_
38-27	5048-5052	T2DM	abstract|person[276]	giv|giv[276]	coref|coref	39-14|39-14
38-28	5053-5061	patients	person[276]	giv[276]	_	_
38-29	5062-5065	and	_	_	_	_
38-30	5066-5068	in	_	_	_	_
38-31	5069-5081	non-diabetic	abstract[277]	new[277]	coref	41-36[309_277]
38-32	5082-5090	subjects	abstract[277]	new[277]	_	_
38-33	5091-5093	in	abstract[277]	new[277]	_	_
38-34	5094-5099	terms	abstract[277]	new[277]	_	_
38-35	5100-5102	of	abstract[277]	new[277]	_	_
38-36	5103-5106	FLI	abstract[277]|abstract	new[277]|giv	coref	41-9
38-37	5107-5108	,	_	_	_	_
38-38	5109-5117	although	_	_	_	_
38-39	5118-5121	the	abstract[279]	new[279]	_	_
38-40	5122-5133	improvement	abstract[279]	new[279]	_	_
38-41	5134-5136	of	abstract[279]	new[279]	_	_
38-42	5137-5142	other	abstract[279]|abstract[280]	new[279]|new[280]	coref	41-22[305_280]
38-43	5143-5153	parameters	abstract[279]|abstract[280]	new[279]|new[280]	_	_
38-44	5154-5155	(	_	_	_	_
38-45	5156-5158	e.	abstract[281]	giv[281]	_	_
38-46	5159-5161	g.	abstract[281]	giv[281]	_	_
38-47	5162-5163	,	abstract[281]	giv[281]	_	_
38-48	5164-5167	HDL	abstract[281]|abstract	giv[281]|new	_	_
38-49	5168-5169	,	abstract[281]	giv[281]	_	_
38-50	5170-5173	LDL	abstract[281]|abstract	giv[281]|new	_	_
38-51	5174-5175	,	abstract[281]	giv[281]	_	_
38-52	5176-5179	and	abstract[281]	giv[281]	_	_
38-53	5180-5182	AP	abstract[281]|abstract	giv[281]|new	_	_
38-54	5183-5184	)	_	_	_	_
38-55	5185-5188	was	_	_	_	_
38-56	5189-5192	not	_	_	_	_
38-57	5193-5195	as	_	_	_	_
38-58	5196-5204	complete	_	_	_	_
38-59	5205-5206	.	_	_	_	_

#Text=These results are in line with a previous study on periodic fasting in T2DM .
39-1	5207-5212	These	abstract[285]	new[285]	coref	41-1[296_285]
39-2	5213-5220	results	abstract[285]	new[285]	_	_
39-3	5221-5224	are	_	_	_	_
39-4	5225-5227	in	_	_	_	_
39-5	5228-5232	line	_	_	_	_
39-6	5233-5237	with	_	_	_	_
39-7	5238-5239	a	abstract[286]	giv[286]	_	_
39-8	5240-5248	previous	abstract[286]	giv[286]	_	_
39-9	5249-5254	study	abstract[286]	giv[286]	_	_
39-10	5255-5257	on	abstract[286]	giv[286]	_	_
39-11	5258-5266	periodic	abstract[286]|abstract[287]	giv[286]|giv[287]	_	_
39-12	5267-5274	fasting	abstract[286]|abstract[287]	giv[286]|giv[287]	_	_
39-13	5275-5277	in	abstract[286]|abstract[287]	giv[286]|giv[287]	_	_
39-14	5278-5282	T2DM	abstract[286]|abstract[287]|event	giv[286]|giv[287]|giv	coref	41-38
39-15	5283-5284	.	_	_	_	_

#Text=Liver enzymes , insulin resistance , and cholesterol levels are related in NAFLD .
40-1	5285-5290	Liver	object|abstract[290]	giv|new[290]	coref|coref|coref|coref	41-13|41-13[302_290]|41-13|41-13[302_290]
40-2	5291-5298	enzymes	abstract[290]	new[290]	_	_
40-3	5299-5300	,	_	_	_	_
40-4	5301-5308	insulin	event|abstract[292]	giv|giv[292]	_	_
40-5	5309-5319	resistance	abstract[292]	giv[292]	_	_
40-6	5320-5321	,	_	_	_	_
40-7	5322-5325	and	_	_	_	_
40-8	5326-5337	cholesterol	abstract[293]	giv[293]	_	_
40-9	5338-5344	levels	abstract[293]	giv[293]	_	_
40-10	5345-5348	are	_	_	_	_
40-11	5349-5356	related	_	_	_	_
40-12	5357-5359	in	_	_	_	_
40-13	5360-5365	NAFLD	substance	giv	_	_
40-14	5366-5367	.	_	_	_	_

#Text=Our results supported a correlation between changes in FLI and changes in liver enzymes ( GGT , and GOT ) and lipid parameters ( TG ) after fasting intervention , although this was limited to subjects without T2DM .
41-1	5368-5371	Our	person|abstract[296]	giv|giv[296]	_	_
41-2	5372-5379	results	abstract[296]	giv[296]	_	_
41-3	5380-5389	supported	_	_	_	_
41-4	5390-5391	a	abstract[297]	new[297]	_	_
41-5	5392-5403	correlation	abstract[297]	new[297]	_	_
41-6	5404-5411	between	abstract[297]	new[297]	_	_
41-7	5412-5419	changes	abstract[297]|abstract[298]	new[297]|new[298]	_	_
41-8	5420-5422	in	abstract[297]|abstract[298]	new[297]|new[298]	_	_
41-9	5423-5426	FLI	abstract[297]|abstract[298]|abstract	new[297]|new[298]|giv	_	_
41-10	5427-5430	and	abstract[297]|abstract[298]	new[297]|new[298]	_	_
41-11	5431-5438	changes	abstract[297]|abstract[298]|abstract	new[297]|new[298]|new	_	_
41-12	5439-5441	in	abstract[297]|abstract[298]	new[297]|new[298]	_	_
41-13	5442-5447	liver	abstract[297]|abstract[298]|object|abstract[302]	new[297]|new[298]|giv|giv[302]	appos|appos	41-16[0_302]|41-16[0_302]
41-14	5448-5455	enzymes	abstract[297]|abstract[298]|abstract[302]	new[297]|new[298]|giv[302]	_	_
41-15	5456-5457	(	_	_	_	_
41-16	5458-5461	GGT	abstract	giv	_	_
41-17	5462-5463	,	_	_	_	_
41-18	5464-5467	and	_	_	_	_
41-19	5468-5471	GOT	_	_	_	_
41-20	5472-5473	)	_	_	_	_
41-21	5474-5477	and	_	_	_	_
41-22	5478-5483	lipid	event|abstract[305]	giv|giv[305]	appos|appos	41-25[0_305]|41-25[0_305]
41-23	5484-5494	parameters	abstract[305]	giv[305]	_	_
41-24	5495-5496	(	_	_	_	_
41-25	5497-5499	TG	abstract	giv	_	_
41-26	5500-5501	)	_	_	_	_
41-27	5502-5507	after	_	_	_	_
41-28	5508-5515	fasting	_	_	_	_
41-29	5516-5528	intervention	event	giv	ana	41-32
41-30	5529-5530	,	_	_	_	_
41-31	5531-5539	although	_	_	_	_
41-32	5540-5544	this	event	giv	_	_
41-33	5545-5548	was	_	_	_	_
41-34	5549-5556	limited	_	_	_	_
41-35	5557-5559	to	_	_	_	_
41-36	5560-5568	subjects	abstract[309]	giv[309]	_	_
41-37	5569-5576	without	abstract[309]	giv[309]	_	_
41-38	5577-5581	T2DM	abstract[309]|abstract	giv[309]|giv	_	_
41-39	5582-5583	.	_	_	_	_
